Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis

PURPOSE: To investigate the efficacy and safety of programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) plus cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies ± other therapies in patients with advanced lung cancer. METHODS: In accordance with the retrieval strategy, we searched...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xiang, Huang, Shangke, Xiao, Hua, Zeng, Shan, Liu, Jiexing, Ran, Zhuolan, Xiong, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811552/
https://www.ncbi.nlm.nih.gov/pubmed/34497128
http://dx.doi.org/10.1136/ejhpharm-2021-002803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811552/
https://www.ncbi.nlm.nih.gov/pubmed/34497128
http://dx.doi.org/10.1136/ejhpharm-2021-002803

Ejemplares similares